Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Open accessThe DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss. Tirzepatide is the first dual GLP-1/GIP receptor co-agonist which has been approved for treatment of type 2 diabetes mellitus (T2DM) based on the findings from the SURPASS program. The SURPASS trials assessed the safety and efficacy of tirzepatide in people with T2DM, from monotherapy through to insulin add-on in global populations, with another two trials dedicated to Japanese population. Over periods of treatment up to 104 weeks, once weekly tirzepatide 5 to 15 mg reduced glycosylated hemoglobin (1.87% to 3.02%), body weight (5.4 to 12.9 kg) and improved multiple cardiometabolic risk factors (including reduction in liver fat, new-onset macroalbuminuria, blood pressure, and lipids) across the T2DM spectrum. Tirzepatide provided better efficacy than placebo and other commonly used glucose-lowering medications such as semaglutide 1 mg, dulaglutide, insulin degludec, and glargine. All tirzepatide doses were well tolerated with similar side-effect profile to the GLP-1 receptor analogues. In people without diabetes, tirzepatide 5 to 15 mg once weekly for the treatment for obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5% to 22.4%) over 72 weeks. Overall, the SURPASS program and SURMOUNT-1 study suggest that tirzepatide is marking a new era in T2DM and/or obesity management through dual agonism of gut hormones.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Selected ongoing clinical trials with tirzepatide (SURPASS program [green boxes], SURMOUNT program [red boxes], and other studies [blue boxes]). SURMOUNT-MMO, A Study of Tirzepatide on the Reduction on Morbidity and Mortality in Adults With Obesity; CV, cardiovascular; SURPASS-CVOT, A Study of Tirzepatide Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes; T2DM, type 2 diabetes mellitus; BMI, body mass index; SURPASSSWITCH, A Study of Tirzepatide in Adult Participants With Type 2 Diabetes Switching From Dulaglutide; HbA1c, glycosylated hemoglobin; SYNERGY-NASH, A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH); NASH, nonalcoholic steatohepatitis; SURMOUNT-OSA, Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide in Participants With Obstructive Sleep Apnea; SUMMIT, A Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; SURPASS-AP-Combo, A Study of Tirzepatide in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea; SURMOUNT-CN, A Study of Tirzepatide in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight.](https://figures.cochat.ai/paper-figures/229b2b689dae4661b9f41e8710a7d739/efficacy-and-safety-of-tirzepatide-in-type-2-diabetes-and-obesity-management-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tirzepatide is the first combination of entero-pancreatic hormones [dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) RA] that has been approved for T2D management based on the findings from the phase 3 SURPASS programme. The marked WL achieved with tirzepatide in the SURPASS trials led to the phase 3 SURMOUNT programme, assessing tirzepatide as treatment for obesity [16].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tirzepatide has been approved for T2D management - the mean HbA1c reduction in SURPASS programme ranged between 1.9 and 2.6% across the trials and 40–69% of participants achieved ≥10% WL with the higher doses (10 and 15 mg), despite that there was no additional support for lifestyle intervention [16, 43].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with type 2 diabetes, pooled tirzepatide 10 mg and 15 mg was associated with consistent and significant improvements in glycaemic control, weight-related measures, and multiple cardiometabolic parameters compared with various comparator treatments in the SURPASS programme.11”
From Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies show that tirzepatide significantly reduced fasting blood glucose and HbA1c levels not only compared to placebo but also compared to degludec and glargine insulins or semaglutide.”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [95]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies in animals have also shown an anorexigenic effect of the GIP and in preclinical studies, the simultaneous activation of GLP-1 and GIP receptors leads to enhanced glucose-lowering effects and more WL compared to activating either receptor alone [21,38,39].”
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Cited by
Items 101–153 of 153
Weight Loss in Diabetes: Pharmacological Management and Other Strategies
Coral, M. I. G. (2023) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2023.17.555953
Chiappini, S., Vickers‐Smith, R., Harris, D. R., Papanti, D., Corkery, J., Guirguis, A., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Preprints.org · doi:10.20944/preprints202309.1300.v1
Luca, F. D., Velardi, V., Candido, R., & Bernardi, S. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01446-3
Recent Progression of Incretin-Based Obesity Treatment
Choi, D. (2024) · Korean Journal of Medicine · doi:10.3904/kjm.2024.99.2.78
Tirzepatide - A Revolution in Obesity Treatment?
Jaroń, A., Jastrzębska, K., Wojciechowska, K., Turek, M., Chaberska, I., Feruś, A., Lipska, J., & Piątkowska, K. (2024) · Quality in Sport · doi:10.12775/qs.2024.17.53102
“[15] In addition, there are other, albeit rarer, side effects associated with taking tirzepatide.”
BackgroundInfluentialde Carvalho, R. S., Braga, M. C., de Oliveira, A. L., Teixeira, T. D. S., Azevedo, L. E. D. L., Crepaldi, L. S., Azevedo, R. C. T., & Cordeiro, N. G. (2024) · International Journal of Nutrology · doi:10.54448/ijn24309
“All doses of tirzepatide were well tolerated, with a side effect profile similar to that of GLP-1 receptor analogues [20] .”
BackgroundCurrent Approach of Diabetes Mellitus in Obese Patients
Karaburgu, S. (2023) · doi:10.69860/nobel.9786053359111.8
Recent Advances in Blood Glucose Management for Diabetic Patients Undergoing Hemodialysis
苏, 俊. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.42237
Navigating the CKM Conundrum: An Integrated Approach to Cardiovascular, Kidney, and Metabolic Health
Cross, L. V., Eichler, C., Jones, E. J., & Mcdaniel, L. (2025) · ADCES in Practice · doi:10.1177/2633559x251333384
Shi, J. (2025) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2024-0393
“This helps identify whether speci fi c groups show consistent Table : Risk ofbias.”
Clinical outcome of off-label drugs for weight loss: a systematic review
Loureiro, T., Michelutti, L. M. D., de Oliveira, S. C., Pontes, M. R., Bianchini, L. B., Búrigo, J. H., Schroff, W. L. A., Schroff, K. J. E., & dos Santos, H. B. (2025) · International Journal of Nutrology · doi:10.54448/ijn25s310
Park, S. J., Rosen, R. L., Muñoz‐Vergara, D., Manson, J. E., Yeh, G. Y., Wayne, P. M., & Sesso, H. D. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5363323
Tratamentos farmacológicos contra a obesidade: uma revisão de escopo
Monteiro, C. T. D. P., de Almeida, G. V., Silva, L. A., & Machado, R. R. P. (2025) · Brazilian Journal of Health Review · doi:10.34119/bjhrv8n4-175
Optimising cardiac surgery outcomes in people with diabetes: the OCTOPuS pilot feasibility study
Holt, R. I. G., Barnard-Kelly, K. D., Patel, M. A., Newland‐Jones, P., Luthra, S., Picot, J., Partridge, H., & Cook, A. (2025) · Health Technology Assessment · doi:10.3310/poyw3311
Torres, J. K. S. (2025) · Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida · doi:10.36692//v17n3-1r
TARGETING MULTIPLE PATHWAYS WITH ONE MOLECULE: THE THERAPEUTIC VERSATILITY OF TIRZEPATIDE
Jędrzejewska-Rzezak, P., Żuczek, A., Dyndał, K., Broda, M., Żuczek, O., Urbańska, K., Szczap, I., Hawryluk, A., Marzec, K., & Mokrzycka, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3902
TIRZEPATIDA: A MAIS NOVA ESPERANÇA NA PERDA DE PESO
Filho, P. D. O. F., Pinto, M. S. L., de Castro, L. D. S., Amorim, Y. C., Zamengo, F. D. O. G., Motta, M. B., & Lima, R. F. D. S. (2025) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v11i11.22190
DIABETE E OBESITÀ: IL RUOLO DELL'AMILINA
BARBIERI, D. (2024) · Electronic Theses and Dissertations Repository (University of Pisa)
Raoui, K. (2023) · Serveur des thèses de l'Université de Strasbourg (University of Strasbourg)
Pharmacologic glycemic management of type 2 diabetes
Mourelatou, N. G., & Rebelos, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00284-3
Sraboni, A., Farhana, K. M., & Abdul, M. K. (2026) · Public Healthcare and Ancient Science · doi:10.64907/xkmf.v6.i1.phas.1
Monitoramento de sinais clínicos em pacientes sob terapia com Tirzepatida
Santos, G. C. P., Magalhães, N. C. O., Borges, T. C. S., de Sousa, A. P., Dias, L. C., Vieira, A. P. N. F., dos Santos, A. M., Santos, D., Pinho, E. C., da Luz, M. E. M., et al. (2026) · Contribuciones a las Ciencias Sociales · doi:10.55905/revconv.19n.1-241
Farmácia Falcão - Porto e nos Serviços Farmacêuticos do Hospital CUF - Porto
Coelho, F. M. L. O. V. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Machado, A. R. D. O. R. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Anti-obesity drugs: comprehensive review and emerging therapies
Marne, P., Patil, S. D., Vora, A., MohdSiddique, M. U., Gadkari, Y. U., & Kurkute, P. (2026) · Endocrine · doi:10.1007/s12020-025-04528-w · Cited by 1
Bednarczyk, R., Bednarczyk, N., Binkowski, R. K., Kurek, A., Krajewska, N., Lejman, A., Mazurkiewicz, A., Sidor, H., Wołosik, M., & Zysiak, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4671
Andrade, F. H. F. D. M. (2026) · International Journal of Nutrology · doi:10.54448/ijn26107
Krzystek, Ł., Buć, K., Buć, P., Mazurek, M., Józefczyk, J., Zieliński, K., Ganczar, K., Jurkowski, S., Rudzińska, M., & Zalewski, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4388
Medenica, S., Prelević, V., Zanković, N., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2648248 · Cited by 1
PHARMACOLOGICAL TREATMENT FOR OBESITY: MECHANISMS OF ACTION, SAFETY AND THERAPEUTIC EFFICACY
dos Santos, R. R. L., Guasti, E. D. P., Nunes, F. M., Leopoldo, A. S., & Lima‐Leopoldo, A. P. (2026) · International Journal of Health Management Review · doi:10.47172/ijhmreview.v12i1.461
“…studies indicate that patients treated with tirzepatide achieved substantially greater mean weight loss and improved metabolic control, reinforcing its superiority as a therapeutic strategy for individuals with type 2 diabetes and concomitant obesity (Małecki et al., 2023; Sinha et al., 2023).”
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
“Tirzepatide, a dual agonist acting on GLP1 and glucose-dependent insulinotropic polypeptide (GIP), was introduced later in the clinical practice and its weight-lowering effects seemed to be even more impressive [14].”
Latt, T. S., Aye, T. T., Ko, K. O. H., Win, S. S., Chit, T. T., & Myint, K. N. S. (2026) · Cureus · doi:10.7759/cureus.106767
Li, J., Li, C., Yang, C., Zhu, Z., Ran, H., Liu, B., Zhang, Y., & Xiang, Y. (2026) · Peptides · doi:10.1016/j.peptides.2026.171489
Clinical Trials and Translational Advances in Metabolic Targeting
Vengateswaran, H. T., Habeeb, M., You, H. W., & Raveendran, C. (2026) · Cancer treatment and research · doi:10.1007/978-3-032-21861-2_13
Mihălțan, F.-D., Borcea, C.-I., & Constantin, A. A. (2026) · Life · doi:10.3390/life16050802
“…in glycemic control may reduce the overall cardiometabolic burden. https://doi.org/10.3390/life16050802 Among patients with established T2DM, tirzepatide has demonstrated significant improvements in glycated hemoglobin levels, with reductions ranging from 1.87% to 3.02% across clinical trials [45].”
InfluentialTirzepatide in the management of heart failure with preserved ejection fraction: A narrative review
Bordoloi, M., Bawankule, S., Acharya, S., & Aggarwal, P. (2026) · Journal of Clinical Sciences · doi:10.4103/jcls.jcls_173_25
Fąfara, M., Jeczkało, M., Kosiorowska, M., Kowalczyk, A., Lasoń, J., Makulska, M., Płachta, W., Sęk, W., Sieradzka, A., & Wegenko, C. M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5796
Tirzepatide: A Paradigm Shift in the Management of Type 2 Diabetes and Obesity
Sonawane, R. A., Gulave, O. K., Kale, P. A., & Rasal, P. B. (2026) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0092
A Patient- and Function-Centric Model/Approach for Hypoglycemia Management in Older Adults
Alagiakrishnan, K., Mereu, L., Rahim, G., Ghosh, M., & Vu, A. (2026) · Geriatrics · doi:10.3390/geriatrics11050118
“These results underscore the need for careful dose adjustment of concurrent glucose-lowering therapies and vigilant blood glucose monitoring when tirzepatide is added to combination regimens [133].”
Carducci, A., Matteo, P. D., Ferri, C., & Grassi, D. (2026) · Cureus · doi:10.7759/cureus.111508
“…greater than semaglutide 1 mg. Similarly, in the 52-week SURPASS-4 trial against titrated insulin glargine, tirzepatide 15 mg achieved an additional 1.14% reduction in HbA1c and an average weight difference of 9.8 kg while avoiding the weight gain typically associated with insulin escalation [1-4].”
InfluentialShil, K. K. (2026) · European journal of medical research · doi:10.1186/s40001-026-04862-3
“In individuals with type 2 diabetes, discontinuation may also be accompanied by worsening HbA1c, which can reinforce weight relapse via increased hyperinsulinemia and reduced support from other therapies [62].”
Zhang, Y., Zhu, B., Peng, B., Wu, P., Zhong, G., Wang, Y., Wang, Z., Feng, X., Tang, D., Peng, D., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70967
“Moreover, Tirzepatide showed a significantly greater efficacy than that of GLP-1R mono-agonist [19–22].”
Cardoso, B. S. A., Lauande, C. C. S., Rodrigues, M. P. C., & Silva, S. E. C. (2026) · DELOS Desarrollo Local Sostenible · doi:10.55905/rdelosv19.n82-035
Reitz, J., Rosoff, D. B., Pacher, P., & Lohoff, F. W. (2026) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2026.100793 · Cited by 1
“Tirzepatide is FDA approved for glycemic con-trol in adults with type 2 diabetes and for chronic weight management in adults with obesity (17,18), but which heavy-drinking populations may benefit clinically is understudied.”
InfluentialExploring on the Hyperinsulinism Management in Women with Polycystic Ovary Syndrome
de Medeiros, S. F., Yamamoto, M. M. W., Jacomeli, J., Soares, J. M., Maciel, G. A. R., & Baracat, E. C. (2026) · Journal of Gynecology and Obstetrics · doi:10.11648/j.jgo.20261403.12
Ayub, M., Abbas, Z., Zubair, H. M., Rizvi, M. I. S., Shams, A., & Aijaz, W. (2026) · Genetics and Molecular Research · doi:10.4238/b94h1957
Lim, S. K., Hwang, Y., Son, J. W., Lee, S., Jung, C. H., Kim, H., Lim, H., Park, S., Kim, J., Youn, J., et al. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e26
Lechi, F., Khalil, A., Bautista, P. N., Öberg, J., Balestri, L. J. I., Eriksson, O., Eriksson, J., & Odell, L. R. (2026) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-026-00486-4
“Mono-and dual receptor targeting incretin mimetics, such as semaglutide (GLP-1R mono-agonist) and tirzepatide (GLP-1R/glucose-dependent insulinotropic polypeptide (GIP) receptor dual agonist), have recently been approved for treatment of T2D and obesity (Sinha et al. 2023).”
Kır, Y., Haymana, C., Torus, B., Güler, B. Y., Uflaz, B., Eroğlu, G., Gursoy, A., Boyraz, E., Akkan, T., Akın, Ş., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03024-w
Shi, Y., Yang, X., Meng, F., Feenstra, K. A., Chen, J., Gu, Z., Gao, X., Yao, W., Dong, G., Gong, L., et al. (2026) · ACS Omega · doi:10.1021/acsomega.6c05930
Efficacy and safety of tirzepatide in the treatment of obesity and obesity-associated comorbidities
Sakhnova, E. E., Gavrilova, N. A., Ostroumova, O. D., Кочетков, А. И., Telkova, S. S., & Moryakova, Y. S. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-324
Tirzepatide: a new treatment for obesity - literature review
Correia, S., Pimenta, A. M., Souto, M. R. S., & Catarino, R. I. L. (2026) · Athena health & research journal. · doi:10.62741/ahrj.v3isuppl.2.199
Obesity Management in Autistic Adults: Toward a Neurodiversity-Informed Approach
Rao, N. P., & Wadford, A. M. (2026) · Autism in Adulthood · doi:10.1177/25739581261497850
Metadata
- Authors
- Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J.
- Affiliations
- University of Leicester (GB)
- Corresponding author
- Papamargaritis, Dimitris
- Venue
- Journal of Obesity & Metabolic Syndrome
- Published
- 2023-02-08
- Volume
- 32
- Issue
- 1
- Pages
- 25-45
- ISSN
- 2508-6235 (ISSN-L)
- 2508-7576
- PMC
- PMC10088547
- OpenAlex
- W4319460325
- Cited by
- 138
- References
- 91
- Citations by year
- 2026: 36 · 2025: 52 · 2024: 35 · 2023: 15
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by-nc)
- Funders
- National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tirzepatide, type 2 diabetes, obesity, GIP/GLP-1 receptor agonist, SURPASS trials, HbA1c, weight loss, cardiometabolic risk factors, drug safety, semaglutide, dulaglutide, insulin degludec, glargine, Japanese population
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.